Abstract
Mutations in STK11 (LKB1) are a major cause of primary resistance to immunotherapy in non–small cell lung cancer. Kitajima and colleagues dissect the underlying mechanism of this immune-resistant phenotype, demonstrating that LKB1 loss leads directly to suppression of stimulator of interferon genes (STING) and insensitivity to cytoplasmic double-strand DNA detection. Therapies that reactivate LKB1 or the STING pathway may boost anticancer immune response in cancers with resistance to immune-checkpoint blockade.
Original language | English (US) |
---|---|
Pages (from-to) | 16-18 |
Number of pages | 3 |
Journal | Cancer discovery |
Volume | 9 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
ASJC Scopus subject areas
- Oncology